Drug Trial Radar · NCT05489614
A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Normal Renal Function and Participants With Various Degrees of Renal Impairment
Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
33
Actual
Start
Sep 13, 2022
Primary completion
Oct 24, 2023
Study completion Dec 19, 2023
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Aug 5, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the pharmacokinetics (PK) of a single dose of olpasiran in participants with normal renal function and participants with various degrees of renal impairment.
Conditions
- Renal Impairment
Interventions
OlpasiranDrug
Participants will receive olpasiran by subcutaneous (SC) injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Observed Serum Concentration (Cmax) of OlpasiranTime frame: Predose, 0.5, 1, 3, 6, 9, 12, 24, 36, 48, 72, 96, 144 hours (postdose), Day 15, and Day 29
- Area Under the Plasma Concentration-time Curve from Time Zero to the Last Quantifiable Concentration (AUClast) of OlpasiranTime frame: Predose, 0.5, 1, 3, 6, 9, 12, 24, 36, 48, 72, 96, 144 hours (postdose), Day 15, and Day 29
- Area Under the Plasma Concentration-time Curve from Time Zero to Infinity (AUCinf) of OlpasiranTime frame: Predose, 0.5, 1, 3, 6, 9, 12, 24, 36, 48, 72, 96, 144 hours (postdose), Day 15, and Day 29
- Dialysis Clearance of Drug From Plasma (CLD) of OlpasiranTime frame: Pre-Dialysis, 0.5, 1, 3 hours after the start of Dialysis, and immediately following the end of Dialysis, Day 1, Day 4
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Inland Empire Clinical Trials, LLC
Rialto, California
CRSCA HC LLC, dba Creekside Post Acute
Yucaipa, California
Clinical Pharmacology Of Miami, LLC
Miami, Florida
Advanced Pharma CR, LLC
Miami, Florida
Orlando Clinical Research Center
Orlando, Florida
Nucleus Network - Minneapolis
Saint Paul, Minnesota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.